Eliem Therapeutics Pre-Tax Income 2021-2024 | CLYM
Eliem Therapeutics pre-tax income from 2021 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Eliem Therapeutics Annual Pre-Tax Income
(Millions of US $) |
| 2023 |
$-35 |
| 2022 |
$-45 |
| 2021 |
$-47 |
| 2020 |
$-21 |
Eliem Therapeutics Quarterly Pre-Tax Income
(Millions of US $) |
| 2024-06-30 |
$-55 |
| 2024-03-31 |
$-2 |
| 2023-12-31 |
$-4 |
| 2023-09-30 |
$-4 |
| 2023-06-30 |
$-5 |
| 2023-03-31 |
$-22 |
| 2022-12-31 |
$-8 |
| 2022-09-30 |
$-10 |
| 2022-06-30 |
$-15 |
| 2022-03-31 |
$-13 |
| 2021-12-31 |
$-11 |
| 2021-09-30 |
$-10 |
| 2021-06-30 |
$-9 |
| 2021-03-31 |
$-19 |
| 2020-12-31 |
|
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
